{"entity":{"id":"nct04270591","kind":"trial","name":"Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer","aka":[],"tldr":"A phase 1/2 trial of Glumetinib in non-small-cell lung cancer, run by Haihe Biopharma Co., Ltd., now recruiting.","summary":"Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer is a phase 1/2 interventional study registered as NCT04270591 by Haihe Biopharma Co., Ltd., with 183 participants planned, started 2019-07-15 and due to reach its primary completion in 2023-10-25. Interventions recorded: Glumetinib.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04270591","url":"https://clinicaltrials.gov/study/NCT04270591"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nsclc","met-altered-nsclc"],"sections":[],"technologies":["kinase-inhibitors"],"targets":[],"drugs":["glumetinib"],"companies":["haihe-biopharma"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-nct04270591-eclinicalmedicine-2023","paper-nct04270591-transl-lung-cancer-res-2025-update"],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04270591","phase":"1/2","setting":"A Phase Ib/II, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of Glumetinib (SCC244), a Selective MET Inhibitor in Patients With Advanced Non-Small Cell Lung Cancer Harboring MET-alterations","sponsor":"Haihe Biopharma Co., Ltd.","started":"2019-07-15","startedType":"actual","enrolled":183,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct04270591/","neighbours":{"cancer":[{"id":"met-altered-nsclc","kind":"cancer","name":"MET exon 14 and MET-amplified non-small-cell lung cancer","route":"/cancers/met-altered-nsclc/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"technology":[{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"glumetinib","kind":"drug","name":"Glumetinib","route":"/drugs/glumetinib/"}],"company":[{"id":"haihe-biopharma","kind":"company","name":"Haihe Biopharma","route":"/companies/haihe-biopharma/"}],"paper":[{"id":"paper-nct04270591-eclinicalmedicine-2023","kind":"paper","name":"Gumarontinib in patients with non-small-cell lung cancer harbouring MET exon 14 skipping mutations: a multicentre, single-arm, open-label, phase 1b/2 trial","route":"/key-papers/paper-nct04270591-eclinicalmedicine-2023/"},{"id":"paper-nct04270591-transl-lung-cancer-res-2025-update","kind":"paper","name":"Long-term follow-up results from the GLORY study: phase II study of gumarontinib in East Asian patients with MET exon 14 skipping mutated non-small cell lung cancer","route":"/key-papers/paper-nct04270591-transl-lung-cancer-res-2025-update/"}]}}